Vanda signed an agreement with Actelion (a subsidiary of Johnson & Johnson) to acquire the US & Canadian rights for Ponvory (ponesimod), an oral S1P1R modulator indicated for the treatment of relapsed forms of multiple sclerosis (MS)
Under the terms of the agreement, Vanda paid Janssen $100M to acquire the rights to distribute Ponvory across the US & Canada. As Vanda takes all the regulatory & supply responsibilities, Janssen will operate the business related to Ponvory according to a Transitional Business License Agreement
Previously, Ponvory depicted proficiency over Aubagio to treat MS with fewer T2 & T1 MRI lesions & no disability progression experienced over 2yrs. in 9/10 patients taking Ponvory
Ref: Vanda Pharma | Image: Vanda Pharma
Related News:- Vanda’s Hetlioz (tasimelteon) Receives the US FDA’s Approval for Nighttime Sleep Disturbances in Smith-Magenis Syndrome
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
